{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "CGON",
  "name": "CG Oncology, Inc.",
  "url": "https://frontierpicks.com/dossiers/CGON/",
  "json_url": "https://frontierpicks.com/dossiers/CGON.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "CG Oncology shares are modestly more likely to beat the S&P 500 over three months after its drug cretostimogene cut bladder-cancer recurrence risk 68% in the Phase 3 PIVOT-006 trial reported on 16 November 2026. The full data at the urology meeting on 2 December 2026 test that result.",
  "invalidation_trigger": "A daily close below $70.15, the lowest close of the week before the PIVOT-006 results (2026-11-12), which would show the trial gain fully given back; or full data on 2026-12-02 showing a low-grade hazard ratio whose confidence interval includes 1.",
  "catalyst_date": "2026-12-02",
  "catalyst_estimated": false,
  "portfolio": null,
  "pick": null,
  "themes": [
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "caveats": [
    {
      "claim": "CG Oncology has no approved product and funds operations from cash; it expects its $984.5 million at 2026-09-30 to last through 2029.",
      "source": "Third-quarter 2026 results release, 2026-11-06",
      "as_of": "2026-11-06"
    },
    {
      "claim": "PIVOT-006 was open-label and compared cretostimogene with surveillance after surgery; the FDA may not agree with the company's reading of the topline results.",
      "source": "CG Oncology PIVOT-006 topline release, 2026-11-16",
      "as_of": "2026-11-16"
    }
  ],
  "source_links": [
    {
      "title": "PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)",
      "url": "https://www.manilatimes.net/2026/11/16/tmt-newswire/globenewswire/pivot-006-phase-3-registrational-trial-demonstrates-unprecedented-improvement-in-recurrence-free-survival-rfs-for-intermediate-risk-and-high-grade-ta-non-muscle-invasive-bladder-cancer-nmibc/2470905",
      "date": "2026-11-16"
    },
    {
      "title": "Cretostimogene reduces recurrence risk by 68% in phase 3 PIVOT-006 trial in NMIBC",
      "url": "https://www.urologytimes.com/view/cretostimogene-reduces-recurrence-risk-by-68-in-phase-3-pivot-006-trial-in-nmibc",
      "date": "2026-11-16"
    },
    {
      "title": "CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates",
      "url": "https://finviz.com/news/418354/cg-oncology-reports-third-quarter-2026-financial-results-and-provides-business-updates",
      "date": "2026-11-06"
    }
  ],
  "evidence": [
    {
      "claim": "PIVOT-006 met its primary endpoint: cretostimogene cut recurrence risk by 68% versus surveillance (hazard ratio 0.32, 95% confidence interval 0.23–0.45) in 367 patients at a median follow-up of 17 months.",
      "source": "CG Oncology PIVOT-006 topline release, 2026-11-16",
      "as_of": "2026-11-16"
    },
    {
      "claim": "PIVOT-006 reported no treatment-related side effects of grade 3 or higher and no treatment-related discontinuations.",
      "source": "CG Oncology PIVOT-006 topline release, 2026-11-16",
      "as_of": "2026-11-16"
    },
    {
      "claim": "After FDA feedback, the BCG-unresponsive BLA was broadened to include high-grade papillary-only disease, with completion now anticipated in March 2027 rather than the fourth quarter of 2026.",
      "source": "CG Oncology releases of 2026-11-06 and 2026-11-16",
      "as_of": "2026-11-16"
    },
    {
      "claim": "The company plans a second BLA, for intermediate-risk and high-grade Ta NMIBC, in the second quarter of 2027, and estimates about 50,000 US patients in that population.",
      "source": "CG Oncology PIVOT-006 topline release, 2026-11-16",
      "as_of": "2026-11-16"
    },
    {
      "claim": "Third-quarter 2026 net loss was $56.9 million, or $0.64 a share; research and development spending was $39.2 million, up from $27.9 million a year earlier.",
      "source": "Third-quarter 2026 results release, 2026-11-06",
      "as_of": "2026-09-30"
    },
    {
      "claim": "Cash, equivalents and marketable securities were $984.5 million, which the company expects to fund operations through 2029.",
      "source": "Third-quarter 2026 results release, 2026-11-06",
      "as_of": "2026-09-30"
    },
    {
      "claim": "Diluted share count rose 15.8% from a year earlier in the quarter to 2026-09-30.",
      "source": "Form 10-Q for the third quarter of 2026",
      "as_of": "2026-09-30"
    }
  ],
  "view_changes": [],
  "frame": {
    "as_of": "2026-11-17",
    "business": "CG Oncology develops cretostimogene grenadenorepvec, a virus placed directly into the bladder that targets non-muscle-invasive bladder cancer. It has no approved product yet. Revenue was $1.6 million in the quarter to 2026-09-30, and the company funds its trials and filings from $984 million of cash and investments.",
    "change": {
      "now": "On 2026-11-16 the company reported that cretostimogene cut recurrence risk 68% versus surveillance in the Phase 3 PIVOT-006 trial in intermediate-risk bladder cancer, and moved completion of its first BLA to March 2027.",
      "next": "Two filings now run in sequence: the broadened BCG-unresponsive BLA by March 2027 and a second BLA in the second quarter of 2027. Research spending rose to $39.2 million in the third quarter of 2026, against $984.5 million of cash.",
      "linked": "Urologists may gain a treatment after surgery where the company says none is approved. Competitors: UroGen (URGN) in intermediate-risk disease; Johnson & Johnson (JNJ), ImmunityBio (IBRX) and enGene (ENGN) in BCG-unresponsive disease."
    },
    "priced_in": "At the 2026-11-16 close (filed inputs to 2026-11-06), the shares trade at 1068.9 times sales and 7.6 times book value. Enterprise value is $6,591 million, the free-cash-flow yield is −2.5%, and earnings multiples are not meaningful. That holds only if cretostimogene wins approval and builds sales from $1.6 million a quarter, against a four-quarter net loss of $237 million.",
    "links": {
      "customers": [],
      "suppliers": [],
      "competitors": [
        {
          "ticker": "JNJ",
          "url": "https://frontierpicks.com/dossiers/JNJ/"
        },
        {
          "ticker": "URGN",
          "url": "https://frontierpicks.com/dossiers/URGN/"
        },
        {
          "ticker": "IBRX",
          "url": "https://frontierpicks.com/dossiers/IBRX/"
        },
        {
          "ticker": "ENGN",
          "url": null
        },
        {
          "ticker": "MRK",
          "url": "https://frontierpicks.com/dossiers/MRK/"
        }
      ]
    }
  },
  "filed_numbers": {
    "as_of": "2026-11-17",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-17",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-06",
              "restated": null,
              "value_musd": 1.6,
              "yoy_pct": -3.7
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-06",
              "restated": null,
              "value_musd": 1.2,
              "yoy_pct": null
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-08",
              "restated": null,
              "value_musd": 1.1,
              "yoy_pct": 1982.7
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-27",
              "restated": null,
              "value_musd": 2.3,
              "yoy_pct": 409.2
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-14",
              "restated": null,
              "value_musd": 1.7,
              "yoy_pct": 3774.4
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-08",
              "restated": null,
              "value_musd": 0,
              "yoy_pct": -100
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-06",
              "restated": null,
              "pct": -66.4
            },
            {
              "end": "2025-09-30",
              "filed": "2026-11-06",
              "restated": null,
              "pct": 5.3
            }
          ]
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-06",
              "restated": null,
              "pct": -3943.2
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-06",
              "restated": null,
              "pct": -7467.7
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-08",
              "restated": null,
              "pct": -6130.1
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-27",
              "restated": null,
              "pct": -2097.3
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-14",
              "restated": null,
              "pct": -3069
            }
          ]
        },
        "pretax_income": {
          "status": "not reported"
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "four_quarters_end": "2026-09-30",
          "value_musd": -56.9,
          "four_quarters_musd": -237.5
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "first_end": "2025-12-31",
          "value_musd": -187.3
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "first_end": "2025-12-31",
          "value_musd": 1.9
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "first_end": "2025-12-31",
          "value_musd": -189.2
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "base_end": "2025-09-30",
          "pct": 15.8
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 984.5
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 3,
          "composition": "non-current long-term debt"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 981.5
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 0,
          "yoy_pct": null
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 0.7
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 1.2
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-06",
          "value_musd": 991
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-11-04",
          "basis_filed": "2026-11-06",
          "value_musd": 7050.8
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-11-04",
          "basis_filed": "2026-11-06",
          "value_musd": 6069.4
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-11-04",
          "basis_filed": "2026-11-06",
          "multiple": 984.3
        },
        "ev_ebit": {
          "status": "not meaningful"
        },
        "pe": {
          "status": "not meaningful"
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-11-04",
          "basis_filed": "2026-11-06",
          "multiple": 7.1
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-11-04",
          "basis_filed": "2026-11-06",
          "pct": -2.7
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-30",
      "published": "2026-11-10",
      "short_pct_of_outstanding": 10.32,
      "days_to_cover": 11,
      "change_pct": 3.9
    },
    "insiders": {
      "status": "not available yet",
      "as_of": null,
      "windows": []
    }
  },
  "body_markdown": "## Current Thesis\nCG Oncology shares are modestly more likely than not to beat the S&P 500 over the next three months. On 2026-11-16 its Phase 3 PIVOT-006 trial gave the bladder-cancer drug cretostimogene a second, larger market. The full data at the Society of Urologic Oncology (SUO) meeting on 2026-12-02 will test whether the result holds up in detail. So will two 12-month datasets due in December 2026.\n\nPIVOT-006 randomly assigned 367 patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) to cretostimogene or to surveillance after their tumours were removed. The company's 2026-11-16 release says cretostimogene cut the risk of recurrence by 68% (hazard ratio 0.32, 95% confidence interval 0.23–0.45). Median follow-up was 17 months, and no patient had a treatment-related side effect of grade 3 or worse. The company puts the US population at about 50,000 patients, with no approved option for treatment after surgery.\n\nThe same release pushed back the first filing. After feedback from the Food and Drug Administration (FDA), the Biologics License Application (BLA) for BCG-unresponsive disease will now also cover high-grade papillary-only tumours, and the company expects to complete it in March 2027. Its 2026-11-06 results release had guided to the fourth quarter of 2026. A second BLA, for intermediate-risk and high-grade Ta disease, is planned for the second quarter of 2027.\n\nThe rating is Medium. The trial result widens the market the shares can price. Against that, the filing comes later, and the market value of $7,572 million at the 2026-11-16 close rests on no product sales.\n\n## Bull Case\n- **Phase 3 met its goal by a wide margin.** The 367-patient randomised trial reported a hazard ratio of 0.32 with p below 0.0001 for recurrence-free survival (company release, 2026-11-16). The company says the benefit appeared in both high-grade and low-grade patients.\n- **Clean safety suits office-based urology.** The trial reported no treatment-related side effects of grade 3 or higher and no treatment-related discontinuations (company release, 2026-11-16).\n- **Cash funds the plan through 2029.** Cash, equivalents and marketable securities were $984.5 million at 2026-09-30, and the company expects them to fund operations through 2029 (third-quarter release, 2026-11-06).\n- **More data arrive before the filing.** Twelve-month data from BOND-003 Cohort P (papillary-only, BCG-unresponsive) and CORE-008 Cohort CX are due in December 2026, after the SUO podium presentation on 2026-12-02 (company releases, 2026-11-06 and 2026-11-16).\n- **The commercial build has started.** The company named Isabel Kalofonos chief commercial officer in October 2026 (third-quarter release, 2026-11-06).\n\n## Bear Case\n- **First filing slipped by a quarter.** Completion of the BCG-unresponsive BLA moved from the fourth quarter of 2026 (2026-11-06 release) to March 2027 (2026-11-16 release), so no FDA review clock starts this year.\n- **Open-label trial against surveillance.** Patients and doctors knew which arm they were in, and the control arm received no drug. The topline release gave no separate high-grade or low-grade figures, and it notes that the FDA may not agree with the company's reading of the results (company release, 2026-11-16).\n- **Valuation rests on future sales.** At the 2026-11-16 close, enterprise value was $6,591 million, or 1068.9 times sales. Over the four quarters to 2026-09-30, net loss was $237 million and free cash flow was negative $189 million (Form 10-Q, 2026-11-06).\n- **Costs and share count are rising.** Research and development spending was $39.2 million in the third quarter of 2026, up from $27.9 million a year earlier, and the diluted share count rose 15.8% from a year earlier (Form 10-Q, 2026-11-06).\n- **Shares fell back from the results-day high.** On 2026-11-16 the stock reached a 52-week intraday high of $93.95, then closed at $84.78, 9.8% below that high.\n\n## Setup & Price Structure\nThe shares closed at $84.78 on 2026-11-16, up from $74.40 on 2026-11-13, the last session before the PIVOT-006 results. In the week before the results, closes ran from $74.74 on 2026-11-09 to a low of $70.15 on 2026-11-12. The intraday high of $93.95 on 2026-11-16 is the 52-week high.\n\nOn adjusted daily closes to 2026-11-16, the 50-day moving average is $68.24 and the 200-day is $66.84, both well below the last close. The 3-month change is 11.1%, measured from $76.29 on 2026-08-18. The 52-week closing low was $37.37 on 2025-12-17, so the shares have more than doubled in eleven months.\n\nThe stock is one case of a one-day jump after news. Across liquid US stocks, no reliable effect has been found so far on returns after jumps of that size, or after a doubling. The levels the case turns on are the 2026-11-16 high, the closes from the week before the results, and the 50-day average.\n\n## Catalyst Calendar\n\n- **2026-12-02:** Full PIVOT-006 results, late-breaking podium presentation at the Society of Urologic Oncology annual meeting. Shows the high-grade and low-grade results, recurrence rates in the control arm and the durability behind the 0.32 hazard ratio, which sets the size of the intermediate-risk market.\n- **December 2026:** Twelve-month data from BOND-003 Cohort P and CORE-008 Cohort CX. Cohort P supports the papillary-only part of the broadened BCG-unresponsive filing; weak durability would put the March 2027 completion at risk.\n- **March 2027:** Completion of the broadened BCG-unresponsive BLA. Starts the FDA review clock for the first approval; a further slip would push launch revenue back again.\n- **Second quarter of 2027:** Planned BLA for intermediate-risk and high-grade Ta NMIBC. Turns the PIVOT-006 result into a filing for the larger market of about 50,000 US patients that the company cites.\n\n## What Would Change Our Mind\n\nA daily close below $70.15, the lowest close of the week before the PIVOT-006 results (2026-11-12), which would show the trial gain fully given back; or full data on 2026-12-02 showing a low-grade hazard ratio whose confidence interval includes 1.\n\nThe risks this note tracks, each with what would confirm it:\n\n- Full PIVOT-006 data show the benefit concentrated in high-grade patients, which would shrink the low-grade intermediate-risk market. Confirmed by: A low-grade subgroup hazard ratio near 1, or one with a wide confidence interval, at the SUO presentation on 2026-12-02.\n- The broadened BCG-unresponsive filing slips again, delaying first revenue. Confirmed by: No announcement of BLA completion by the end of March 2027, or a company statement moving the date.\n- The FDA questions the open-label design with surveillance as the control for the intermediate-risk filing. Confirmed by: A company disclosure that the FDA requested more data or another study before the planned second-quarter 2027 BLA.\n- The company sells new shares after the rally, adding to a share count already up 15.8% from a year earlier. Confirmed by: An 8-K or prospectus supplement announcing an equity offering.\n- Competing bladder-cancer treatments take the intermediate-risk or BCG-unresponsive market first. Confirmed by: A Phase 3 result or label expansion in intermediate-risk NMIBC from UroGen (URGN) or Johnson & Johnson (JNJ).\n\n## Correlation Notes\nThe shares trade mostly on company events: trial results, filing dates and FDA steps. The November 2026 moves line up with the 2026-11-06 results and the 2026-11-16 trial release. A common market view is that mid-cap biotech shares also move with the biotech sector and with interest-rate expectations.\n\nNews from competitors in bladder cancer bears directly on the commercial case. In intermediate-risk disease the competitor is UroGen (URGN). In BCG-unresponsive disease the competitors are Johnson & Johnson (JNJ), ImmunityBio (IBRX), Merck (MRK) and enGene (ENGN). A rival's trial result or label expansion would change how much of the intermediate-risk market cretostimogene can win.",
  "first_seen": "2026-11-16",
  "last_analyzed": "2026-11-17T03:34:39+00:00",
  "last_synthesized": "2026-11-17",
  "date_modified": "2026-11-17",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}